Switch theme
Sign up to access all valuation multiples
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
2000
10.6K+
LTM Revenue $33.4B
LTM EBITDA $12.4B
$34.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Novonesis has a last 12-month revenue (LTM) of $33.4B and a last 12-month EBITDA of $12.4B.
In the most recent fiscal year, Novonesis achieved revenue of $577M and an EBITDA of $156M.
Novonesis expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Novonesis valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $33.4B | XXX | $577M | XXX | XXX | XXX |
| Gross Profit | $16.8B | XXX | $273M | XXX | XXX | XXX |
| Gross Margin | 50% | XXX | 47% | XXX | XXX | XXX |
| EBITDA | $12.4B | XXX | $156M | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | 27% | XXX | XXX | XXX |
| EBIT | $6.4B | XXX | $99.2M | XXX | XXX | XXX |
| EBIT Margin | 19% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $4.2B | XXX | $46.1M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 8% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Novonesis's stock price is DKK 462 (or $70).
Novonesis has current market cap of DKK 215B (or $32.4B), and EV of DKK 226B (or $34.0B).
See Novonesis trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $34.0B | $32.4B | XXX | XXX | XXX | XXX | $1.36 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Novonesis has market cap of $32.4B and EV of $34.0B.
Novonesis's trades at 58.9x EV/Revenue multiple, and 217.7x EV/EBITDA.
Equity research analysts estimate Novonesis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Novonesis has a P/E ratio of 58.2x.
See valuation multiples for Novonesis and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $32.4B | XXX | $32.4B | XXX | XXX | XXX |
| EV (current) | $34.0B | XXX | $34.0B | XXX | XXX | XXX |
| EV/Revenue | 7.6x | XXX | 58.9x | XXX | XXX | XXX |
| EV/EBITDA | 20.5x | XXX | 217.7x | XXX | XXX | XXX |
| EV/EBIT | 39.8x | XXX | 342.7x | XXX | XXX | XXX |
| EV/Gross Profit | 15.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 58.2x | XXX | 703.3x | XXX | XXX | XXX |
| EV/FCF | 42.4x | XXX | 342.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNovonesis's last 12 month revenue growth is 9%
Novonesis's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $16K for the same period.
Novonesis's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Novonesis's rule of X is 60% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Novonesis and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 198% | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | 14% | XXX | 303% | XXX | XXX | XXX |
| Rule of 40 | 40% | XXX | 36% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 60% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $16K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 30% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Borouge | XXX | XXX | XXX | XXX | XXX | XXX |
| Fertiglobe | XXX | XXX | XXX | XXX | XXX | XXX |
| Akzo Nobel | XXX | XXX | XXX | XXX | XXX | XXX |
| Avantium | XXX | XXX | XXX | XXX | XXX | XXX |
| DSM Firmenich | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Novonesis acquired XXX companies to date.
Last acquisition by Novonesis was XXXXXXXX, XXXXX XXXXX XXXXXX . Novonesis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Novonesis founded? | Novonesis was founded in 2000. |
| Where is Novonesis headquartered? | Novonesis is headquartered in Denmark. |
| How many employees does Novonesis have? | As of today, Novonesis has 10.6K+ employees. |
| Who is the CEO of Novonesis? | Novonesis's CEO is Ms. Ester Baiget. |
| Is Novonesis publicy listed? | Yes, Novonesis is a public company listed on CSE. |
| What is the stock symbol of Novonesis? | Novonesis trades under NSIS B ticker. |
| When did Novonesis go public? | Novonesis went public in 2000. |
| Who are competitors of Novonesis? | Similar companies to Novonesis include e.g. Borouge, Fertiglobe, Akzo Nobel, Avantium. |
| What is the current market cap of Novonesis? | Novonesis's current market cap is $32.4B |
| What is the current revenue of Novonesis? | Novonesis's last 12 months revenue is $33.4B. |
| What is the current revenue growth of Novonesis? | Novonesis revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Novonesis? | Current revenue multiple of Novonesis is 7.6x. |
| Is Novonesis profitable? | Yes, Novonesis is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Novonesis? | Novonesis's last 12 months EBITDA is $12.4B. |
| What is Novonesis's EBITDA margin? | Novonesis's last 12 months EBITDA margin is 37%. |
| What is the current EV/EBITDA multiple of Novonesis? | Current EBITDA multiple of Novonesis is 20.5x. |
| What is the current FCF of Novonesis? | Novonesis's last 12 months FCF is $6.0B. |
| What is Novonesis's FCF margin? | Novonesis's last 12 months FCF margin is 18%. |
| What is the current EV/FCF multiple of Novonesis? | Current FCF multiple of Novonesis is 42.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
